Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies
- PMID: 26254030
- DOI: 10.1016/S1470-2045(15)00212-0
Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies
Abstract
Background: Oral contraceptives are known to reduce the incidence rate of endometrial cancer, but it is uncertain how long this effect lasts after use ceases, or whether it is modified by other factors.
Methods: Individual participant datasets were sought from principal investigators and provided centrally for 27 276 women with endometrial cancer (cases) and 115 743 without endometrial cancer (controls) from 36 epidemiological studies. The relative risks (RRs) of endometrial cancer associated with oral contraceptive use were estimated using logistic regression, stratified by study, age, parity, body-mass index, smoking, and use of menopausal hormone therapy.
Findings: The median age of cases was 63 years (IQR 57-68) and the median year of cancer diagnosis was 2001 (IQR 1994-2005). 9459 (35%) of 27 276 cases and 45 625 (39%) of 115 743 controls had ever used oral contraceptives, for median durations of 3·0 years (IQR 1-7) and 4·4 years (IQR 2-9), respectively. The longer that women had used oral contraceptives, the greater the reduction in risk of endometrial cancer; every 5 years of use was associated with a risk ratio of 0·76 (95% CI 0·73-0·78; p<0·0001). This reduction in risk persisted for more than 30 years after oral contraceptive use had ceased, with no apparent decrease between the RRs for use during the 1960s, 1970s, and 1980s, despite higher oestrogen doses in pills used in the early years. However, the reduction in risk associated with ever having used oral contraceptives differed by tumour type, being stronger for carcinomas (RR 0·69, 95% CI 0·66-0·71) than sarcomas (0·83, 0·67-1·04; case-case comparison: p=0·02). In high-income countries, 10 years use of oral contraceptives was estimated to reduce the absolute risk of endometrial cancer arising before age 75 years from 2·3 to 1·3 per 100 women.
Interpretation: Use of oral contraceptives confers long-term protection against endometrial cancer. These results suggest that, in developed countries, about 400 000 cases of endometrial cancer before the age of 75 years have been prevented over the past 50 years (1965-2014) by oral contraceptives, including 200 000 in the past decade (2005-14).
Funding: Medical Research Council, Cancer Research UK.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Comment in
-
The Pill's gestation: from birth control to cancer prevention.Lancet Oncol. 2015 Sep;16(9):1004-1006. doi: 10.1016/S1470-2045(15)00211-9. Epub 2015 Aug 4. Lancet Oncol. 2015. PMID: 26254029 No abstract available.
Similar articles
-
Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls.Lancet. 2008 Jan 26;371(9609):303-14. doi: 10.1016/S0140-6736(08)60167-1. Lancet. 2008. PMID: 18294997
-
Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study.Am J Obstet Gynecol. 2017 Jun;216(6):580.e1-580.e9. doi: 10.1016/j.ajog.2017.02.002. Epub 2017 Feb 8. Am J Obstet Gynecol. 2017. PMID: 28188769
-
Time-Dependent Effects of Oral Contraceptive Use on Breast, Ovarian, and Endometrial Cancers.Cancer Res. 2021 Feb 15;81(4):1153-1162. doi: 10.1158/0008-5472.CAN-20-2476. Epub 2020 Dec 17. Cancer Res. 2021. PMID: 33334812
-
Oral contraceptives and breast disease.Fertil Steril. 1991 Nov;56(5):799-819. doi: 10.1016/s0015-0282(16)54647-0. Fertil Steril. 1991. PMID: 1936311 Review.
-
[Oral contraceptives and endometrial and ovarian carcinomas].Gynakol Geburtshilfliche Rundsch. 1998;38(2):105-8. doi: 10.1159/000022244. Gynakol Geburtshilfliche Rundsch. 1998. PMID: 9815528 Review. German.
Cited by
-
DNA Damage Responses in Tumors Are Not Proliferative Stimuli, but Rather They Are DNA Repair Actions Requiring Supportive Medical Care.Cancers (Basel). 2024 Apr 19;16(8):1573. doi: 10.3390/cancers16081573. Cancers (Basel). 2024. PMID: 38672654 Free PMC article. Review.
-
Recent Advances in Endometrial Cancer Prevention, Early Diagnosis and Treatment.Cancers (Basel). 2024 Mar 1;16(5):1028. doi: 10.3390/cancers16051028. Cancers (Basel). 2024. PMID: 38473385 Free PMC article. Review.
-
Incorporating biological and clinical insights into variant choice for Mendelian randomisation: examples and principles.eGastroenterology. 2024 Jan;2(1):e100042. doi: 10.1136/egastro-2023-100042. Epub 2024 Jan 22. eGastroenterology. 2024. PMID: 38362310 Free PMC article.
-
Age at menopause is inversely related to the prevalence of common gynecologic cancers: a study based on NHANES.Front Endocrinol (Lausanne). 2023 Nov 16;14:1218045. doi: 10.3389/fendo.2023.1218045. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38034008 Free PMC article.
-
Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022). Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer, Geriatric Assessment and Supply Structures.Geburtshilfe Frauenheilkd. 2023 Aug 15;83(8):919-962. doi: 10.1055/a-2066-2051. eCollection 2023 Aug. Geburtshilfe Frauenheilkd. 2023. PMID: 37588260 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
